Professor Paul Moss

Paul Moss.School of Cancer Sciences Day 1 110311.

Professor Moss’s research is focussed around the application of translational immunological research in the study of human cancer.

Institute of Immunology and Immunotherapy

Director of Research and Knowledge Transfer, Professor of Haematology


UoB profile


Background and Research focus

Professor Paul Moss is the Deputy Head of College of Medical and Dental Sciences and Director of Research and Knowledge Transfer. His research is focused on the application of translational immunological research in the study of human malignancies. Paul’s current research team comprises clinical and non-clinical research scientists working on a wide range of projects. His group is particularly interested in developing strategies to optimize stem cell transplantation (SCT) for patients with haematological malignancies. Despite the curative potential of SCT for haematological malignancies, patients are at risk of mortality due to disease relapse, graft versus host disease (GvHD) and infection.  One aspect of Paul’s research involves examining the mechanisms that govern the graft versus leukaemia (GvL) effect and GvHD, with the aim of boosting GvL and reducing GvHD. His team also has a strong interest in tumour associated antigens, including cancer testis antigens, minor histocompatibility antigens, epigenetically modified antigens as well as antigens for innate immune recognition. This work has progressed to clinical trials testing pre-transplant donor vaccination strategies to selectively boost GvL responses. Paul also has a long-standing research interest in Cytomegalovirus (CMV), a herpesvirus that in healthy individuals is asymptomatic but can cause severe illness in immunocompromised transplant patients. In light of this, Paul and his team have developed novel adoptive T cell therapies to combat CMV reactivation in immunocompromised individuals. Latterly, his research interests have expanded to include solid tumour immunology, especially testicular cancer. Collectively, his research is likely to facilitate design of improved immunotherapy strategies targeted at cancer.



Haematological malignancies; multiple myeloma; transplantation; leukemia; lymphoma; tumour antigens; tumour immunotherapy; testicular cancer; MHC tetramer; adoptive transfer; CMV; adoptive T cell therapy.


Other activities

Professor Moss is an honorary consultant at the University Hospitals Birmingham NHS Foundation Trust. His primary interests are in haemato-oncology and general haematology and he is the Clinical Service Lead for chronic lymphocytic leukaemia. Professor Moss is currently Chair of the Infections and Immunity Board at the Medical Research Council. In this role he oversees funding in basic, clinical and translational research applied to infectious human disease and to disorders of the human immune system. He also serves as a member of the Strategy Board at the MRC. Professor Moss is also a member of the Scientific Advisory Board of Cell Medica.



Chakupurakal G, Onion D, Bonney S, Cobbold M, Mautner V, Moss P. HLA-peptide multimer selection of adenovirus-specific T cells for adoptive T-cell therapy. J Immunother. 2013 Oct;36(8):423-31.

Frumento G, Zheng Y, Aubert G, Raeiszadeh M, Lansdorp PM, Moss P, Lee SP, Chen FE. Cord blood T cells retain early differentiation phenotype suitable for immunotherapy after TCR gene transfer to confer EBV specificity. Am J Transplant. 2013 Jan;13(1):45-55.

Antoun A, Vekaria D, Salama RA, Pratt G, Jobson S, Cook M, Briggs D, Moss P. The genotype of RAET1L (ULBP6), a ligand for human NKG2D (KLRK1), markedly influences the clinical outcome of allogeneic stem cell transplantation. Br J Haematol. 2012 Dec;159(5):589-98.

Croudace JE, Inman CF, Abbotts BE, Nagra S, Nunnick J, Mahendra P, Craddock C, Malladi R, Moss PA. Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells  plays a major role in the pathogenesis of chronic GVHD. Blood. 2012 Nov 15;120(20):4246-55.

Goodyear OC, Dennis M, Jilani NY, Loke J, Siddique S, Ryan G, Nunnick J, Khanum R, Raghavan M, Cook M, Snowden JA, Griffiths M, Russell N, Yin J, Crawley  C, Cook G, Vyas P, Moss P, Malladi R, Craddock CF. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012 Apr 5;119(14):3361-9.

Oliver C Goodyear, Mike Dennis, Nadira Y Jilani, Justin Loke, Shamyla Siddique, Gordon Ryan, Jane Nunnick, Rahela Khanum, Manoj Raghavan, Mark Cook, John a Snowden, Mike Griffiths, Nigel Russell, John Yin, Charles Crawley, Gordon Cook, Paresh Vyas, Paul Moss, Ram Malladi, Charles F Craddock (2012) Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).Blood 119 (14), 3361-9.

Shetty S, Bruns T, Weston CJ, Stamataki Z, Oo YH, Long HM, Reynolds GM, Pratt G, Moss P, Jalkanen S, Hubscher SG, Lalor PF, Adams DH. Recruitment mechanisms of primary and malignant B cells to the human liver. Hepatology. 2012 Oct;56(4):1521-31.

Skowronska A, Parker A, Ahmed G, Oldreive C, Davis Z, Richards S, Dyer M, Matutes E, Gonzalez D, Taylor AM, Moss P, Thomas P, Oscier D, Stankovic T. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. J Clin Oncol. 2012 Dec 20;30(36):4524-32.

Goodyear OC, Pearce H, Pratt G, Moss P. Dominant responses with conservation of T-cell receptor usage in the CD8+ T-cell recognition of a cancer testis antigen peptide presented through HLA-Cw7 in patients with multiple myeloma. Cancer Immunol Immunother. 2011 Dec;60(12):1751-61.

Piper KP, Karanth M, McLarnon A, Kalk E, Khan N, Murray J, Pratt G, Moss PA.  Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cells. Clin Exp Immunol. 2011 Nov;166(2):154-63.

Simpson AA, Mohammed F, Salim M, Tranter A, Rickinson AB, Stauss HJ, Moss PA,  Steven NM, Willcox BE. Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restriction. Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21176-81.